TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28206674

Group type: EXPERIMENTAL
Intervention: SCS-ON (Spinal Cord Stimulation, 50 Hz, 210-μs pulse duration, 12 hours daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: SCS-OFF (No Spinal Cord Stimulation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SCS-ON
Number of subjects: 13

Group type: COMPARATOR
Intervention: SCS-OFF
Number of subjects: 13
Study: 25898052

Group type: EXPERIMENTAL
Intervention: Oral insulin (67.5 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral insulin (22.5 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral insulin (2.5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 25
Study: 23460732

Group type: EXPERIMENTAL
Intervention: Hospitalization due to worsening heart failure (WHF)
Number of subjects: 6558

Group type: EXPERIMENTAL
Intervention: Hospitalization due to myocardial infarction (MI)
Number of subjects: 6558

Group type: COMPARATOR
Intervention: Not hospitalized for WHF or MI
Number of subjects: 6558

Group type: EXPERIMENTAL
Intervention: First WHF hospitalization
Number of subjects: 6558

Group type: EXPERIMENTAL
Intervention: First MI hospitalization
Number of subjects: 6558
Study: 22007909

Group type: EXPERIMENTAL
Intervention: 10% urea-based lotion (Ureadin Rx 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glycerol-based emollient cream (Dexeryl)
Number of subjects: 30
Study: 18226982

Group type: EXPERIMENTAL
Intervention: Unbanded LRYGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Banded LRYGB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16490584

Group type: EXPERIMENTAL
Intervention: Test formulation (Sensibit)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference formulation (Clarityne)
Number of subjects: 32
Study: 12499977

Group type: EXPERIMENTAL
Intervention: High dose antithrombin (AT group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment alone (nonAT group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COT levels at hospital admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine coagulation tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COT
Number of subjects: 0
Study: 12832314

Group type: EXPERIMENTAL
Intervention: Repaglinide/metformin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Nateglinide/metformin
Number of subjects: 192
Study: 11234559

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of calcipotriol and diflucortolone valerate ointment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Combination therapy (calcipotriol and diflucortolone valerate)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 63
Study: 8672752

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (n = 61)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Polyethylene glycol (n = 55)
Number of subjects: 116
Study: 1646775

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6491703

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (15 mg/kg by rapid intravenous injection X 3) plus radiation (3,750 rad in 24 fractions)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No surgical adjuvant therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Treatment refusal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Local-regional component of first clinical recurrence
Number of subjects: 62
Study: 30826763

Group type: EXPERIMENTAL
Intervention: Access to Renewed digital intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Access to Renewed digital intervention with brief human support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29848902

Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 25237981

Group type: EXPERIMENTAL
Intervention: AAB (Theramine) alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of AAB and ibuprofen
Number of subjects: 122
Study: 24768476

Group type: EXPERIMENTAL
Intervention: 10 min CWI in 6 °C
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 min CWI in 10 °C
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Short intermittent CWI (1 min × 3 at 10 °C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Short contrast immersion (1 min 38 °C/1 min 10 °C × 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 50
Study: 22455381

Group type: EXPERIMENTAL
Intervention: Shared-care intervention (multidisciplinary obesity clinic appointment followed by regular GP appointments over 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared-care intervention
Number of subjects: 0
Study: 20883560

Group type: EXPERIMENTAL
Intervention: ATG-Fresenius plus reduced-dose tacrolimus monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus plus steroids
Number of subjects: 0
Study: 17700333

Group type: EXPERIMENTAL
Intervention: Early surgery (n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard surgery (n = 27)
Number of subjects: 56
Study: 16046455

Group type: EXPERIMENTAL
Intervention: Growth hormone administration (GH) 6 IU/day for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 16
Study: 12153969

Group type: EXPERIMENTAL
Intervention: Once-daily 2.5 mg rhDNase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alternate-day 2.5 mg rhDNase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-daily 7% HS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of daily rhDNase with alternate-day rhDNase and HS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Changes in NE activity
Number of subjects: 48
Study: 10915394

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/HCTZ 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 10 mg/HCTZ 25 mg
Number of subjects: 0
Study: 7872282

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.i.d.
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg q.i.d.
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 2370014

Group type: EXPERIMENTAL
Intervention: Cyclosporin 5-7.5 mg/kg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 61
Study: 27370

Group type: EXPERIMENTAL
Intervention: Penbutolol 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Practolol 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol and Practolol
Number of subjects: 12
Study: 31332775

Group type: EXPERIMENTAL
Intervention: Single-injection Erector Spinae Plane Block (ESPB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multiple-injection Costotransverse Block (MICB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-injection Thoracic Paravertebral Block (TPVB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multiple-injection Thoracic Paravertebral Block (TPVB)
Number of subjects: 10
Study: 28452195

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg/day)
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study: 25485803

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 44 U (CFL: 24 U, GL: 20 U)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 24 U (CFL: 24 U, GL: placebo)
Number of subjects: 917

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 917
Study: 24950523

Group type: EXPERIMENTAL
Intervention: Palliative Care Extended Packages at Home (PEACH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20973811

Group type: EXPERIMENTAL
Intervention: Moderate-intensity home-based walking program for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 40
Study: 18337551

Group type: EXPERIMENTAL
Intervention: Intravenous mesna 5 mg/kg thrice weekly before dialysis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17228988

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 12812248

Group type: COMPARATOR
Intervention: Geriatric patients (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Younger patients (group 2)
Number of subjects: 40
Study: 11298071

Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remacemide with phenobarbitone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenobarbitone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desglycinyl metabolite of remacemide
Number of subjects: 12
Study: 9143454

Group type: EXPERIMENTAL
Intervention: Best Tracer Method (BTM) for soil ingestion estimation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional methods for soil ingestion estimation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Adult validation study
Number of subjects: 64
Study: 7912949

Group type: EXPERIMENTAL
Intervention: 2-Hz stimulation once every 10 s
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2-Hz stimulation once every 20 s
Number of subjects: 24
Study: 3234474

Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg t.d.s.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1663423

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1275213

Group type: EXPERIMENTAL
Intervention: Preoperative haemodilution with haematocrit lowered to 24.8%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Preoperative haemodilution limited to haematocrit 27%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Haemodilution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparable surgical procedures without haemodilution
Number of subjects: 46
Study: 31269926

Group type: EXPERIMENTAL
Intervention: NAP SACC UK intervention with Health Visitor support, staff training workshops, and web-based parent support; implemented in five of six intervention nurseries.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 12
Study: 28741272

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of 11.25 mg hyperbaric bupivacaine with morphine 150 µg and fentanyl 15 µg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of 15 mg hyperbaric bupivacaine with morphine 150 µg and fentanyl 15 µg
Number of subjects: 30
Study: 26034004

Group type: COMPARATOR
Intervention: Baseline clinical assessment alone
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Laboratory data
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Complete model
Number of subjects: 2331
Study: 23349254

Group type: EXPERIMENTAL
Intervention: Biostimine (Aloe arborescens Mill. extract), 1 ampoule once daily for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biostimine (Aloe arborescens Mill. extract)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21224829

Group type: EXPERIMENTAL
Intervention: Small portion size of hot meals offered in addition to existing size
Number of subjects: 308

Group type: COMPARATOR
Intervention: Proportional pricing
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Small meal purchases
Number of subjects: 308
Study: 19650798

Group type: EXPERIMENTAL
Intervention: Rocuronium infusion at CSM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rocuronium infusion at APM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine-facilitated recovery at CSM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neostigmine-facilitated recovery at APM
Number of subjects: 30
Study: 17186970

Group type: EXPERIMENTAL
Intervention: CBA-BMS
Number of subjects: 521

Group type: COMPARATOR
Intervention: BA-BMS
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: IVUS-CBA-BMS
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Angio-CBA-BMS
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: IVUS-BA-BMS
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Angio-BA-BMS
Number of subjects: 521
Study: 14663908

Group type: EXPERIMENTAL
Intervention: Intratumoral chemotherapy with cytostatic drugs and prednisolone during bronchofibroscopy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 28
Study: 11827729

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 0
Study: 8999375

Group type: EXPERIMENTAL
Intervention: Constant propofol infusion of 200 micrograms/kg/min during the pre-bypass period and fentanyl boluses of 1 mg when required (PH Group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Variable propofol infusion (from 43.09 to 22.42 micrograms/kg/min) during the pre-bypass period and a fixed infusion of 10.47 micrograms/kg/min during the post-bypass period (PL Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% isoflurane administration throughout the intraoperative period (F Group)
Number of subjects: 30
Study: 1473327

Group type: EXPERIMENTAL
Intervention: Integrated diabetes care system with enhanced role of diabetes specialist nurse
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard unaltered clinics
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Integrated diabetes care system
Number of subjects: 700
Study: 6507711

Group type: EXPERIMENTAL
Intervention: Heel pads, ultrasound, and exercises
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ultrasound and exercises
Number of subjects: 33
Study: 31634245

Group type: EXPERIMENTAL
Intervention: Novel ultrasound group (acoustic shadowing)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Traditional ultrasound group
Number of subjects: 79
Study: 28850378

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray (V)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo spray (S)
Number of subjects: 300
Study: 26323735

Group type: EXPERIMENTAL
Intervention: Ketamine plus propofol (Ketofol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 60
Study: 23311540

Group type: EXPERIMENTAL
Intervention: 4 gm MgSO4 as a single bolus (Group A, 16 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 8 gm MgSO4 (two 4 gm doses q4H) (Group B, 8 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 12 gm MgSO4 (three 4 gm doses q4H) (Group C, 8 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 16 gm MgSO4 (four 4 gm doses q4H) (Group D, 8 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Control group, 10 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 16 gm MgSO4
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 50
Study: 21711463

Group type: EXPERIMENTAL
Intervention: Achillea millefolium extract at 2% for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycolic acid (reference resurfacing molecule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achillea millefolium extract
Number of subjects: 0
Study: 19419855

Group type: EXPERIMENTAL
Intervention: Dacarbazine with oblimersen
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Dacarbazine, cisplatin, interferon‐alfa‐2b with/without interleukin‐2
Number of subjects: 1085
Study: 16886975

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 4,000 mg over 15 min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 2,500 mg over 5 min
Number of subjects: 48

Group type: COMPARATOR
Intervention: Levetiracetam (LEV) administered IV
Number of subjects: 48
Study: 15617949

Group type: EXPERIMENTAL
Intervention: Blind group (active drug and placebo)
Number of subjects: 4295

Group type: COMPARATOR
Intervention: Nonblind group (active drug and no treatment)
Number of subjects: 4295

Group type: EXPERIMENTAL
Intervention: Blind group
Number of subjects: 4295

Group type: COMPARATOR
Intervention: Nonblind group
Number of subjects: 4295
Study: 11020259

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum, Lactobacillus acidophilus and oligofructose (c.1011 cfu of B. longum BB 536 and L. acidophilus NCFB 1748 and 15 g oligofructose daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oligofructose only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9345328

Group type: COMPARATOR
Intervention: PBSCT
Number of subjects: 48

Group type: COMPARATOR
Intervention: alloBMT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 8246751

Group type: EXPERIMENTAL
Intervention: Theophylline slow-release tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline syrup
Number of subjects: 0
Study: 3898281

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg administered subcutaneously)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30216777

Group type: EXPERIMENTAL
Intervention: Experimental prosocial condition (children told the prize would go to another child)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition (children told they would keep the prize for themselves)
Number of subjects: 240
Study: 31050816

Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 0
Study: 27506185

Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 195
Study: 25113246

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Posterior subtenon triamcinolone (PST)
Number of subjects: 30
Study: 24083754

Group type: EXPERIMENTAL
Intervention: Docetaxel and cyclophosphamide six-cycle therapy (TC6)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC)
Number of subjects: 43
Study: 21459680

Group type: COMPARATOR
Intervention: Celecoxib 100 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Celecoxib 50 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Celecoxib 100 mg followed by 50 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Celecoxib 50 mg bid
Number of subjects: 269
Study: 18366084

Group type: EXPERIMENTAL
Intervention: Pneumatic skin flattening (PSF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment using the dynamic cooling device (DCD)
Number of subjects: 40
Study: 16547714

Group type: COMPARATOR
Intervention: Innovator cyclosporine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Generic cyclosporine
Number of subjects: 28
Study: 15385220

Group type: EXPERIMENTAL
Intervention: Classroom-based harm minimization programme conducted in two phases over 2 years.
Number of subjects: 2300
Study: 11204035

Group type: EXPERIMENTAL
Intervention: Common spatial patterns analysis of EEG
Number of subjects: 3
Study: 9414975

Group type: EXPERIMENTAL
Intervention: Fedotozine 30 mg three times daily
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 8503552

Group type: EXPERIMENTAL
Intervention: Higher doses of allergen-antibody complexes (Group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lower doses of allergen-antibody complexes (Group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 39
Study: 3493493

Group type: EXPERIMENTAL
Intervention: Interferential current stimulation (ICS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 40
Study: 30400116

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2, 2.5, and 3 mA for 20 minutes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS (2, 2.5, and 3 mA for 20 minutes)
Number of subjects: 9
Study: 28780558

Group type: EXPERIMENTAL
Intervention: Active Play in ASP intervention (7-month duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 25461493

Group type: EXPERIMENTAL
Intervention: Shockable rhythm 1min post-shock
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Shockable rhythm immediately before next possible shock
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Return of spontaneous circulation (ROSC)
Number of subjects: 1657
Study: 23116683

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 666

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 666
Study: 21040126

Group type: EXPERIMENTAL
Intervention: Mucosal advancement flap (MAF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 18
Study: 18209768

Group type: EXPERIMENTAL
Intervention: Low absolute hematocrit values during follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decreases in hematocrit during follow-up compared with baseline
Number of subjects: 0
Study: 17030680

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amiodarone therapy
Number of subjects: 104
Study: 12746781

Group type: EXPERIMENTAL
Intervention: Continue secondary prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinue secondary prophylaxis
Number of subjects: 0